Dr. Michael Schlossmacher helped establish a key concept in Alzheimer’s disease and is now investigating the link between Parkinson’s and the immune system.

As a young medical student in Austria, Michael Schlossmacher and his fellow students had to prepare a report on the possible causes of stomach ulcers. They stuck with all the conventional theories and got a good grade, but the report turned out to be totally wrong. At the time, evidence was just starting to emerge that stomach ulcers could be caused by a bacterium, but the establishment did not want to hear it. It was just too radical.

When the truth came to light, Dr. Schlossmacher resolved that he would never again accept medical dogmas without questioning them and he wouldn’t be afraid to investigate opposing ideas.

This approach has led to many surprising and important discoveries, netting Dr. Schlossmacher the 2017 Grimes Research Career Achievement Award from The Ottawa Hospital.

After completing his medical training, Dr. Schlossmacher obtained a scholarship to visit Harvard University in Boston. With his mentor, Dr. Dennis Selkoe, he studied amyloid-beta protein, which accumulates in the brains of people with Alzheimer’s disease. He discovered that this protein is produced by all cells in the body, a revolutionary finding that is now a cornerstone of our understanding of Alzheimer’s.

In 2006, Dr. Schlossmacher was recruited to The Ottawa Hospital and the University of Ottawa, attracted in part by Ottawa’s collaborative, multi-disciplinary Parkinson’s Research Consortium. He eventually assumed leadership of the hospital’s neuroscience research program and founded the University of Ottawa’s MD-PhD program.

In recent years, Dr. Schlossmacher has pioneered the still-to-be-proven theory that Parkinson’s could be triggered by an infection, particularly in people who are genetically at risk. This is based partly on large, long-running human observational studies and partly on molecular studies of two Parkinson’s-associated genes, called alpha-synuclein and LRRK2.

“If the theory is correct, it would mean Parkinson’s could be triggered by an infection decades before motor symptoms actually develop,” said Dr. Schlossmacher. “We think that select infections in the gut or nose might cause the innate immune system to malfunction, and this could eventually lead to inflammation in the brain and damage of critical nerve cells. If proven correct, this would allow us to predict who may develop Parkinson’s in later years. It would also provide hope for new treatments for this still incurable disease.”

Dr. Schlossmacher and his team have made other important discoveries. For example, they dissected the pathway that links alpha-synuclein and GBA1. This led to a clinical trial of an experimental therapy for Parkinson’s in 2017. His team also developed a spinal fluid test for alpha-synuclein that is now used in all large observational studies of Parkinson’s progression.

Dr. Schlossmacher said his scientific approach is inspired by his patients, rooted in teamwork, and fuelled by a willingness to challenge widespread assumptions, whether they be his own, or someone else’s.

“My mother always taught me to be daring and to reassemble the pieces of a puzzle to see whether we can create a different view, and thus a better understanding of a problem,” said Dr. Schlossmacher.  “That’s something I love doing more than anything.”

8 things most people don’t know about Dr. Michael Schlossmacher

• Failed his entrance exam to Grade 1
• In grade school, aspired to be a professional pencil sharpener; in high school to become a professional soccer player (before a knee injury)
• Attended a Jesuit-run boarding school in Austria for eight years
• Was awarded a Fulbright scholarship to visit Harvard University
• Is married to his wife, Elke (who grew up in Hawaii), and has four children
• Participates in many fundraisers for the hospital, including THE RIDE, Dancing with the Docs and Lap the Gats
• Became a proud Canadian citizen in 2016
• Favourite quote: “I know that I know nothing” by Socrates

Dr. Schlossmacher’s research is supported by generous donations to The Ottawa Hospital, particularly through the Bhargava Research Chair in Neurodegeneration. He is also supported by the Canadian Institutes of Health Research, the Ontario Brain Institute, the Michael J. Fox Foundation, Parkinson Canada, the Weston Brain Institute and the Parkinson Research Consortium.

Celine Peladeau - November 8, 2017

I am forever inspired by rebel spirit

Support patient care and research at
The Ottawa Hospital

Donate Now

You might also like…

A special video message for International Women’s Day

Every year on March 8, we recognize International Women’s Day to celebrate how far we have come with equal rights and opportunities for women, and to acknowledge how far we still have left to go. This video is a short-but-sweet reminder that the women who work for our organization are driven, caring, innovative and powerful.

Celebrate our Staff, Leadership, Working Together

New Research Chair in Gay Men’s Health is setting out to break down barriers to care

As both a researcher and a gay man, Dr. Paul MacPherson knows all too well the stigma that gay men often face in the health-care system. Now, as the Clinical Research Chair in Gay Men’s Health at The Ottawa Hospital and the University of Ottawa, he’s on a mission to make quality health care more accessible to this often overlooked patient population.

Mental Health, Research, Sexual Health

Healing through art: Congratulations to the winners of the TRIAS Art Prize

Did you know that art has the power to heal? This year, The Ottawa Hospital and the Ottawa Art Gallery launched the TRIAS Art Prize to recognize the role of artists in healing and wellness. We recently announced the winners, and you’ll see their artwork around the hospital in the new year. Get a sneak preview today.

Awards, Community Engagement, Wellness

The Ottawa Hospital administers world-first in-utero treatment for rare genetic disorder

Before Ayla was born, she had already made history. Last year at The Ottawa Hospital, she received a world-first in-utero treatment for Pompe disease, a rare genetic disorder that had taken the lives of two of her siblings. Now 17 months old, Ayla is healthy and happy.

Fetal Health, Infant Health, Innovation

A look to the future: Six innovations coming to our campuses

As we set out to build one of the most advanced hospitals in the country, we’re often asked what we have planned for our existing campuses. From installing new equipment to opening long-term care homes, we have a number of projects in the works to enhance and expand our world-class services at all our locations.

Innovation, New Campus Development

Made-in-Ottawa tool helps decide when critically ill patients can breathe on their own

Over the past two years of the pandemic, more Canadians than ever have required mechanical ventilation to help them breathe. The Ottawa Hospital is the first hospital in the world to evaluate an innovative medical device that uses artificial intelligence to predict when critically ill patients are ready to breathe on their own.

Innovation, Research

This website gives you common facts, advice and tips. Some of it may not apply to you. Please talk to your doctor, nurse or other health-care team member to see if this information will work for you. They can also answer your questions and concerns.